Clozapine modified-release - Intas Pharmaceuticals

Drug Profile

Clozapine modified-release - Intas Pharmaceuticals

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Intas Pharmaceuticals
  • Class Antipsychotics; Dibenzazepines
  • Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Muscarinic receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 18 May 2016 Chemical structure information added
  • 12 May 2016 No recent reports on development identified - Phase-I for Schizophrenia in India (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top